Asset profile
MK0653A, ezetimibe (+) simvastatin
Small molecule
Evidence outlook · lead readout
NCT00110435 · Type 2 Diabetes Mellitus, Hypercholesterolemia
The completed lead evidence has the design features that historically survive confirmatory trials: randomized, controlled, and adequately powered against a prespecified clinically accepted endpoint.
NCT00110435: This was a randomized, double-blind, active-controlled trial of 1,229 patients. Ezetimibe/simvastatin produced significantly larger reductions in LDL cholesterol than atorvastatin at each dose pairing tested, a clinically important and statistically significant advantage.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
63 competitors in this universe: 3 direct rivals (same mechanism and indication), 0 same-class, 60 same-indication; 18 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| MK0653A, Ezetimibe (+) Simvastatin: this drug | Phase 3 | Small molecule | HMG-CoA reductase / NPC1L1 | ||
| AG2304R | Phase 3 | Small molecule | HMG-CoA reductase / NPC1L1 | ||
| Atozet (ezetimibe / Atorvastatin) | Not yet studied | Small molecule | HMG-CoA reductase / NPC1L1 | ||
| Rosuvamibe | Not yet studied | Small molecule | HMG-CoA reductase / NPC1L1 | ||
| Alirocumab (Praluent) | Approved | Monoclonal antibody | PCSK9 | ||
| Bempedoic Acid (Nexletol) | Approved | Small molecule | Adenosine Triphosphate-Citrate Lyase Inhibitor, ATP citrate lyase | ||
| Bempedoic Acid / Ezetimibe | Approved | Small molecule | ATP citrate lyase (ACLY, bempedoic acid) and NPC1L1 (ezetimibe) | ||
| Cangrelor (Kengreal) | Approved | Small molecule | P2Y12 receptor | ||
| Colchicine (cardiovascular) (Lodoco) | Approved | Small molecule | Microtubule/inflammasome (tubulin) | ||
| Dapagliflozin (Farxiga / Forxiga) | Approved | Small molecule | SGLT2 | ||
| Dulaglutide (Trulicity) | Approved | Peptide | GLP-1 receptor | ||
| Evolocumab (Repatha) | Approved | Monoclonal antibody | PCSK9 | ||
| Icosapent Ethyl (Vascepa) | Approved | Small molecule | Omega-3 fatty acid (EPA) | ||
| Inclisiran (Leqvio) | Approved | RNA / oligonucleotide | PCSK9 | ||
| Liraglutide (Saxenda / Victoza) | Approved | Peptide | GLP-1 receptor | ||
| Lomitapide (Juxtapid) | Approved | Small molecule | MTP |
…and 48 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.